Bridged bicyclic aryl or heteroaryl substituted triazoles and pharmaceuticalcompositions containing the compoundsare disclosed as being useful in inhibiting the activity of the receptorprotein tyrosine kinase Ax1. Methods of using the compoundsin treating diseases or conditions associated with Ax1 activity are alsodisclosed.